학술논문
Lenalidomide, rituximab (R2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Document Type
Article
Author
Source
In: Leukemia and Lymphoma . (Leukemia and Lymphoma, 2024, 65(6):768-773)
Subject
Language
English
ISSN
10292403
10428194
10428194